Atomoxetine

Research use only, not for human use.

Atomoxetine ((R)-Tomoxetine;LY-139603) is a potent, selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM.

Atomoxetine ((R)-Tomoxetine;LY-139603) is a potent, selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM; shows weak affinity for 5-HT and dopamine transporters with IC50 of 77 and 1,451 nM, respectively; has been approved for the treatment of attention deficit hyperactivity disorder (ADHD).Parkinson Disease Phase 3 Clinical.

Atomoxetine (Tomoxetine) (1-100 μM; 0.5-20 seconds; tsA201 cells) interacts with the human heart muscle sodium channel (hNav1.5) in a state and dose-dependent manner.

Atomoxetine (Tomoxetine) (0.3-3 mg/kg; i.p.; 0-4 hours; male Sprague-Dawley rats) increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression in the rat prefrontal cortex.Atomoxetine (Tomoxetine) (0.1-5 mg/kg; i.p. and p.o; for 14 days; spontaneously hypertensive rat) can improve behaviors associated with ADHD in rats. Animal Model:Male Sprague-Dawley ratsDosage:0.3, 1 and 3 mg/kg Administration: Intraperitoneal injection; for 4 hours Result:Increased the number of cells expressing Fos-like immunoreactivity in PFC 3.7-fold and increased extracellular norepinephrine and dopamine by 3-fold.Animal Model:Spontaneously hypertensive rat (SHR)Dosage:0.1, 0.3, 1.25 and 5.0 mg/kg Administration:Intraperitoneal injection and oral administration; for 14 days Result:Had non-impact on the measurement of motor activity.

R)-Tomoxetine | LY-139603

Membrane Transporter/Ion Channel

Monoamine Transporter

Monoamine Transporter

Neurological Disease

Parkinson Disease

83015-26-3

255.361

C17H21NO

>98% (HPLC)

——

CC1=CC=CC=C1O[C@@H](C2=CC=CC=C2)CCNC

(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine

(-20℃)

With Ice Pack

≥ 2 years